Epidermodysplasia verruciformis: Unsuccessful therapeutic approach with imiquimod

International Journal of Dermatology

Volumn 46, Issue SUPPL. 3, 2007, Pages 45-47

  Janssen, Kathleen ^a,b,c   Lucker, Georges P H ^a,b,c   Houwing, Ronald H ^a,b,c   van Rijssel, R ^a,b,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Sittard Geleen Heerlen   (Netherlands)

^c DEVENTER HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; IMIQUIMOD;

ADULT; ARTICLE; CANCER SURGERY; CASE REPORT; CELLULAR IMMUNITY; CLINICAL EXAMINATION; DRUG TREATMENT FAILURE; DYSKERATOSIS; EPIDERMODYSPLASIA VERRUCIFORMIS; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 8; INFECTION SENSITIVITY; MALE; POLYMERASE CHAIN REACTION; SEBORRHEIC KERATOSIS; SKIN BIOPSY; SQUAMOUS CELL CARCINOMA; TINEA VERSICOLOR; TREATMENT OUTCOME; VIRUS INFECTION; WART VIRUS;

AMINOQUINOLINES; EPIDERMODYSPLASIA VERRUCIFORMIS; HUMANS; MALE; MIDDLE AGED; TREATMENT FAILURE;

EID: 35648979012     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2007.03513.x     Document Type: Article

References (16)

1. Majewski S, Jablonska S. Do epidermodysplasia verruciformis human papillomaviruses contribute to malignant and benign epidermal proliferations? Arch Dermatol 2002; 138: 649-654.
2. Lewandowsky F, Lutz W. Ein Fall einer bisher nicht beschriebenen Hauterkrankungn (Epidermodysplasia verruciformis). Arch Dermatol Syphilol 1922; 12: 306-316.
3. Majewski S, Jablonska S. Epidermodysplasia verruciformis of a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995; 131: 1312-1318.
4. Hannuksela-Svahn A, Nordal E, Christensen OB. Treatment of multiple superficial basal cell carcinomas on the scalp with imiquimod 5% cream. Acta Derm Venereol (Stockholm) 2000; 80: 381-382.
5. Mackenzie-Wood Q, Kossard S, DeLauney J, et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44: 462-470.
6. Ramoz N, Rueda LA, Bouadjar B, et al. A susceptibility locus for epidermodysplasia verruciformis, an abnormal predisposition to infection with the oncogenic human papilloma virus type 5, maps to chromosome 17qter in a region containing a psoriasis locus. J Invest Dermatol 1999; 112: 259-263.
7. Ramoz N, Taieb A, Rueda LA, et al. Evidence for a nonallelic heterogenecity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p41 and 17q51. J Invest Dermatol 2000; 114: 1148-1153.
8. Ramoz N, Rueda LA, Bouadjar B, et al. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002; 32: 579-581.
9. Majewski S, Jablonska S. Skin autografts in epidermodysplasia verruciformis: Human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. Cancer Res 1997; 57: 4214-4216.
10. Jablonska S. Epidermodysplasia Verruciformis. Philadelphia: W.B. Saunders, 1991.
11. Orth G. Epidermodysplasia verruciformis. In: Salzman NP, Howley PM, eds. The Papovaviridae: The Papillomaviruses. New York: Plenum Publishing Corporation, 1987: 199-235.
12. Boxman ILA, Berkhout RJM, Mulder LHC, et al. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997; 108: 712-715.
13. Slade HB, Owens ML, Thomai MA, et al. Imiquimod 5% cream. Exp Opin Invest Drugs 1998; 7: 437-449.
14. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-141.
15. Hu W, Nuovo G, Willen M, Somach S. Epidermodysplasia verruciformis in two half brothers with HIV infection. J Cutan Med Surg 2004; 8: 357-360.
16. Berthelot C, Dickerson M, Rady P, et al. Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol 2007; 56: 882-886.